Effect of antiobesity medications in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 11, Issue 7, 2009, Pages 641-664

  Choussein, Souzana ^a   Makri, Angeliki A ^a   Frangos, Constantinos C ^a   Petridou, Eleni Th ^a   Daskalopoulou, Stella S ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Antiobesity drugs; Obesity; Orlistat; Rimonabant; Sibutramine; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; BIPHASIC INSULIN; CETILISTAT; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAMLINTIDE; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ABNORMAL DREAMING; AGITATION; BEHAVIOR THERAPY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEFECATION; DEPRESSION; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FECES; FLATULENCE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSOMNIA; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANIC; PULSE RATE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

EID: 70349748654     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01026.x     Document Type: Review

References (129)

1. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes Res 1998, 6(Suppl. 2):51S-209S.
2. Public Health Agency of Canada. Preventing Chronic Diseases: A Vital Investment 2005, http://www.who.int/chp/chronic%5Fdisease%5Freport/contents/en/index.htm, Geneva, World Health Organization; Public Health Agency of Canada, Available online
3. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev 2007, 29:1-5.
4. Kumar PJ, Clark ML. Kumar and Clark Clinical Medicine 2005, 252-257. 6th edn, New York, Elsevier Saunders
5. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
6. Patel MR, Donahue M, Wilson PW, Califf RM. Clinical trial issues in weight-loss therapy. Am Heart J 2006, 151:633-642.
7. Scheen AJ, Ernest P. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat. Diabetes Metab 2002, 28:437-445.
8. Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
9. Tuomilehto J, Lindstrom J, Eriksson JG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
10. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 1998, 68:899-917.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
13. Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diabetes Spectrum 2007, 20:159-165.
14. Cheah JS. Anti-obesity. Current management of obesity. Singapore Med J 1996, 37:299-303.
15. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984, 144:1143-1148.
16. Inoue S, Egawa M, Satoh S. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Am J Clin Nutr 1992, 55:199S-202S.
17. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006, 29:49-60.
18. McKay RH. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973, 1:489-493.
19. Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004, 12:1197-1211.
20. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994, 18:129-135.
21. Schteingart DE. Effectiveness of phenylpropanolamine in the management of moderate obesity. Int J Obes Relat Metab Disord 1992, 16:487-493.
22. Poston WS, Foreyt JP. Scientific and legal issues in fenfluramine/dexfenfluramine litigation. Tex Med 2000, 96:48-56.
23. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003, CD004094
24. Chou KM, Huang BY, Fanchiang JK, Chen CH. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients. Chang Gung Med J 2007, 30:538-546.
25. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004, 17:222-229.
26. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 2001, 24:1957-1960.
27. Hung YJ, Chen YC, Pei D. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with type 2 diabetes. Diabet Med 2005, 22:1024-1030.
28. Wang TF, Pei D, Li JC. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2005, 59:746-750.
29. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2000, 2:105-112.
30. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003, 26:125-131.
31. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002, 19:119-124.
32. Fujioka K, Seaton TB, Rowe E. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000, 2:175-187.
33. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2004, 26:1427-1435.
34. Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord 2004, 28:600-605.
35. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006, 29:2137-2139.
36. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005, 21:457-468.
37. Ryan DH. Clinical use of sibutramine. Drugs Today (Barc) 2004, 40:41-54.
38. Jung SH, Park HS, Kim KS. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J Nutr Biochem 2008, 19:371-375.
39. Rubio MA, Gargallo M, Isabel Millan A, Moreno B. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr 2007, 10:1200-1205.
40. Sramek JJ, Leibowitz MT, Weinstein SP. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens 2002, 16:13-19.
41. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 2005, 29:509-516.
42. Torp-Pedersen C, Caterson I, Coutinho W. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007, 28:2915-2923.
43. Birkenfeld AL, Schroeder C, Boschmann M. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002, 106:2459-2465.
44. Scholze J. [Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters]. Dtsch Med Wochenschr 2002, 127:606-610.
45. Sharma AM, Caterson ID, Coutinho W. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2008, Epub ahead of print
46. McNeely W, Benfield P. Orlistat. Drugs 1998, 56:241-249.
47. Toplak H, Ziegler O, Keller U. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005, 7:699-708.
48. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med 2005, 22:612-618.
49. Keating GM, Jarvis B. Orlistat: in the prevention and treatment of type 2 diabetes mellitus. Drugs 2001, 61:2107-2119.
50. Halpern A, Mancini MC, Suplicy H. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003, 5:180-188.
51. Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases - a six-month randomized trial. Diabetes Obes Metab 2004, 6:375-383.
52. Bergholm R, Tiikkainen M, Vehkavaara S. Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003, 26:1667-1672.
53. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002, 4:415-423.
54. Kelley DE, Bray GA, Pi-Sunyer FX. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002, 25:1033-1041.
55. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004, 27:33-40.
56. Heymsfield SB, Segal KR, Hauptman J. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000, 160:1321-1326.
57. Richelsen B, Tonstad S, Rossner S. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study. Diabetes Care 2007, 30:27-32.
58. Tan KC, Tso AW, Tam SC, Pang RW, Lam KS. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 2002, 19:944-948.
59. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000, 248:245-254.
60. Swinburn BA, Carey D, Hills AP. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005, 7:254-262.
61. Hollander PA, Elbein SC, Hirsch IB. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
62. Kuo CS, Pei D, Yao CY, Hsieh MC, Kuo SW. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Int J Clin Pract 2006, 60:906-910.
63. Miles JM, Leiter L, Hollander P. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002, 25:1123-1128.
64. Shi YF, Pan CY, Hill J, Gao Y. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed type 2 diabetes. Diabet Med 2005, 22:1737-1743.
65. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
66. Davidson MH, Hauptman J, DiGirolamo M. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235-242.
67. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000, 9:160-167.
68. Sjostrom L, Rissanen A, Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998, 352:167-172.
69. Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol 2002, 440:109-117.
70. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab 2003, 5:195-201.
71. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006, 60:1697-1706.
72. Bermudez-Silva FJ, Suarez J, Baixeras E. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008, 51:476-487.
73. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784.
74. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
75. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008, 51:1356-1367.
76. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672.
77. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007, 132:2239-2252.
78. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. SERENADE: the study evaluating rimonabant efficacy in drug-naive diabetic patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008, 31:2169-2176.
79. Scheen AJ. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol 2008, 20(Suppl. 1):139-146.
80. Search of: diabetes obesity-list results. 2008, http://clinicaltrials.gov/ct2/results?term=rimonabant+diabetes, Available from URL, Accessed September 2008
81. Hollander P, Amod A, Litwak L. Rimonabant improves glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial (Abstract). Diabetes 2008, 57(Suppl. 1).
82. Bhatt D. Rimonabant improves glycemic control in insulin-treated type 2 diabetes (ARPEGGIO). 2008, http://www.cardiosource.com/clinicaltrials/trial.asp?trialID=1713, Available from URL, Accessed September 2008
83. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 2007, 120:S18-S28.
84. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A. The SERENADE trial: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naive type 2 diabetes. Diabetes Care 2008, 31:2169-2176.
85. Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007, 21:535-553.
86. Lafontan M, Piazza PV, Girard J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 2007, 33:85-95.
87. Scheen AJ. The endocannabinoid system, a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 2009, 10:56-74.
88. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006, 47:1919-1926.
89. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
90. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
91. Nissen SE, Nicholls SJ, Wolski K. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008, 299:1547-1560.
92. Davis SN, Perkins JM. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. Endocr Pract 2007, 13:790-804.
93. Van Gaal L, Pi-Sunyer X, Despres JP, McCarthy C, Scheen A. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program. Diabetes Care 2008, 31(Suppl. 2):S229-S240.
94. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
95. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008, 29:1761-1771.
96. The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia (press release). http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf, Avaliable from URL, Accessed September 2008
97. Redmon JB, Reck KP, Raatz SK. Two-year outcome of a combination of weight loss therapies for type 2 diabetes. Diabetes Care 2005, 28:1311-1315.
98. Tankova T, Dakovska G, Lazarova M, Dakovska L, Kirilov G, Koev D. Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol 2004, 41:146-153.
99. Garber A. Glucagon-like peptide-1-based therapies: new developments and emerging data. Diabetes, Obesity and Metabolism 2008, 10:22-35.
100. Hays NP, Galassetti PR, Coker RH. Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions. Pharmacol Ther 2008, 118:181-191.
101. Mafong DD, Henry RR. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep 2008, 10:55-60.
102. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006, 29:435-449.
103. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
104. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
105. Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
106. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
107. Barnett AH, Burger J, Johns D. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007, 29:2333-2348.
108. Nauck MA, Duran S, Kim D. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
109. Ratner RE, Maggs D, Nielsen LL. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006, 8:419-428.
110. Blonde L, Klein EJ, Han J. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006, 8:436-447.
111. Kim D, MacConell L, Zhuang D. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
112. Yu BS, Wang AR. Glucagon-like peptide 1 based therapy for type 2 diabetes. World J Pediatr 2008, 4:8-13.
113. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
114. Drucker DJ, Buse JB, Taylor K. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
115. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004, 27:1335-1342.
116. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008, 14:363-380.
117. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007, 59:151-184.
118. Hollander P, Maggs DG, Ruggles JA. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004, 12:661-668.
119. Ratner RE, Want LL, Fineman MS. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002, 4:51-61.
120. Kopelman P, Bryson A, Hickling R. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 2007, 31:494-499.
121. Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Investig Drugs 2008, 9:414-421.
122. 2008, http://www.alizyme.com/alizyme/products/cetilistat/, Available from URL, Accessed September 2008
123. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004, 27:155-161.
124. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 Jan 25;(1):CD004096
125. Norris SL, Zhang X, Avenell A. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004, 164:1395-1404.
126. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007, 335:1194-1199.
127. Scheen AJ. Exenatide once weekly in type 2 diabetes. Lancet 2008, 372:1197-1198.
128. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002, 26:262-273.
129. Wing RR, Epstein LH, Nowalk MP, Koeske R, Hagg S. Behavior change, weight loss, and physiological improvements in type II diabetic patients. J Consult Clin Psychol 1985, 53:111-122.